This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis

This study has been completed.
Information provided by:
Alcon Research Identifier:
First received: May 30, 2006
Last updated: November 17, 2016
Last verified: June 2008
The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunctivitis.

Condition Intervention Phase
Allergic Conjunctivitis Drug: olopatadine 0.2% Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Comparative Study of Olopatadine 0.2% Versus Vehicle in Patients With Seasonal Allergic Conjunctivitis or Rhinoconjunctivitis

Resource links provided by NLM:

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Daily signs and symptoms scores during the 14 days of peak pollen

Secondary Outcome Measures:
  • Patients with daily signs and symptoms scores of zero during the 14 days of peak pollen

Estimated Enrollment: 250
Study Start Date: August 2006
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   10 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • History of seasonal allergic conjunctivitis or rhinoconjunctivitis, a positive grass antigen challenge reaction (skin test), and a positive response to grass in the Conjunctival Allergen Challenge (CAC) model

Exclusion Criteria:

  • Under 10 years of age
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00331500

United States, Texas
Alcon Research, Ltd.
Fort Worth, Texas, United States, 76134
Sponsors and Collaborators
Alcon Research
Study Director: Stella Robertson Study Director
  More Information

Publications: Identifier: NCT00331500     History of Changes
Other Study ID Numbers: C-04-60
Study First Received: May 30, 2006
Last Updated: November 17, 2016

Additional relevant MeSH terms:
Conjunctivitis, Allergic
Conjunctival Diseases
Eye Diseases
Hypersensitivity, Immediate
Immune System Diseases
Olopatadine Hydrochloride
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Anti-Allergic Agents
Histamine H1 Antagonists, Non-Sedating
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on July 21, 2017